FOLH1 and neuroendocrine neoplasm: New radiopharmaceuticals such as Lutetium prostate specific membrane antigen (PSMA) have been proposed with regards to treatment of prostate cancer8and proven safe effective in randomized trials.9Other established theranostic pathways, such as Lutetium 177 DOTA Octreotate for Neuroendocrine tumors, as well as access to new clinical trials are still deficient in the NT.